BioSpace News Archive

Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT).

Olympus announced the availability of several Experience Papers focused on the benefits of advancements in electrosurgical devices.

Axcella Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator compositions, announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue.

Conformis, Inc., a leading medical device company that features personalized knee and hip replacement products, announced it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023.

Inotiv, Inc. announced that David Landman has been designated by Jermyn Street Associates LLC as its Shareholder Representative on the Board of Directors, replacing Scott Cragg, who is stepping down to focus on his position as Partner at AS Birch Grove.

Smart Immune SAS announced today that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial Sloan Kettering Cancer Center (MSK).

OncXerna Therapeutics, Inc. announced final results from a Phase 2 trial of bavituximab plus pembrolizumab in patients with previously untreated advanced hepatocellular carcinoma and new biomarker data demonstrating that the Xerna™ TME Panel clearly identified trial participants more likely to benefit from treatment.

TScan Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) applications for T-Plex, TSC-204-A0201, and TSC-204-C0702.

Compugen Ltd. announced today that Anat Cohen-Dayag , Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities C-Suite Series to discuss Compugen’s leadership in the DNAM-1 axis.

Castle Biosciences, Inc. today announced that the Company’s medical director, Matthew Goldberg, M.D., F.A.A.D., board-certified dermatologist and dermatopathologist, will present at the Precision Medicine World Conference (PMWC®) 2023, being held Jan. 25-27 in Santa Clara, California.